HPGA Restoration Enclomiphene HCG Gonadorelin

The big idea

If your testosterone is low, you have a choice: replace it from outside (TRT — exogenous testosterone) or restart your own production from inside (one of the four peptides on this page). The two paths produce very different downstream consequences for fertility, native production, and long-term dependency.

This article is for the user who wants to understand the four upstream-of-TRT levers — Enclomiphene, HCG, Gonadorelin, Kisspeptin — and figure out which one matches the specific failure point in their own HPG axis. That’s the precision-medicine framing both one practitioner and Chris Neal (NP) converge on: your blood work is your audit report, and the right tool depends on where the audit shows the breakdown.

Alyve availability: None of the four peptides on this page is in Alyve’s current launch 15-SKU catalog. All four are roadmap candidates as the catalog expands. The Alyve cross-sell that is available now for users running any of these or TRT itself is Ipamorelin (or the CJC-1295 / Ipamorelin blend) — restoring the GH pulsatility that exogenous testosterone suppresses (one practitioner’s explicit recommendation).

---

The HPG axis — the mechanism map you need first

One practitioner’s “Fortune 500” framing is the cleanest way to hold the whole system in one breath. Neal’s cascade-flow framing layers in two extra details (kisspeptin neuron at the top, aromatase + DHT at the bottom). Combined:

HYPOTHALAMUS
  Kisspeptin neuron → produces kisspeptin
    ↓
  GnRH neuron (arcuate nucleus) → produces GnRH (pulsatile)
    ↓
PITUITARY (gonadotroph cells)
  → produces LH + FSH
    ↓
TESTICLES
  LH → Leydig cells (steroidogenesis from cholesterol via cAMP) → testosterone
  FSH → Sertoli cells → spermatogenesis + androgen-binding protein
    ↓
BLOODSTREAM testosterone splits three ways:
  → stays as testosterone (androgen receptor activation)
  → converts to DHT (5-α reductase) — more potent androgen
  → converts to estradiol (aromatase)
    ↑
  Estrogen feedback → hypothalamus on/off switch
    Too much estrogen → switch flips OFF → entire cascade shuts down

Two things to internalize:

1. Rhythm is the master code. GnRH is pulsatile — the frequency and amplitude of pulses determine everything downstream. A flat constant signal does not produce the same output as a pulsatile one. This matters most for Gonadorelin protocols (must be dosed pulsatile, not as a single daily bolus) and for the Kisspeptin half-life problem (it doesn’t last long enough to produce sustained signaling from a single dose).
2. Estrogen, not testosterone itself, flips the negative-feedback switch. Both one practitioner and Neal converge on this. When TRT “shuts you down,” it’s the estradiol your body aromatizes from the exogenous testosterone that signals “we’re done here” to the hypothalamus. The on/off switch is upstream of GnRH; everything south of it (LH, FSH, Leydig, Sertoli) shuts down together. This is why aromatase inhibitors (anastrozole, exemestane, letrozole) exist as a separate tool class — they reduce the conversion, which removes the off-signal.

Decision algorithm — which lever, and when

One practitioner’s primary-vs-secondary framework and Neal’s cascade-failure-point framework map onto each other cleanly:

What the blood work shows	Where the failure is	Tool
LH high + T low	Primary hypogonadism — factory is broken (Leydig cells defective)	Testosterone (TRT) — replacement is the right tool. Native production can’t be rescued.
LH low or inappropriately normal + T low; estradiol high (e.g., on TRT or from obesity)	Estrogen feedback off-switch is stuck	Enclomiphene — block the estrogen feedback, the brain restarts the cascade
LH low + factory intact, want to keep it running on TRT or restore after a cycle	Pituitary or downstream stays online	HCG — direct LH-mimetic activation of Leydig cells
GnRH-to-pituitary signal insufficient (less common, often after long-term suppression)	Hypothalamus-to-pituitary step	Gonadorelin — provide the GnRH signal directly, pulsatile dosing
Failure at the very top — kisspeptin neuron not initiating cascade	Top of the cascade	Kisspeptin — the upstream-most lever

Your blood work is the audit report. Total T, free T, LH, FSH, estradiol, SHBG. That panel tells you where in the cascade the breakdown is. The question isn’t which peptide is “best”; it’s which one matches your specific failure point.

The TRT-vs-Enclomiphene framing (one practitioner, the headline framing of this whole cluster):

• Exogenous testosterone = total replacement. Floods receptors → maximum negative feedback → CEO slashes GnRH → COO stops LH/FSH → both Leydig and Sertoli cells shut down → native production becomes redundant → fertility crashes → you commit to being the supplier for the rest of your life (or you exit very carefully).
• Enclomiphene = native stimulation. SERM with higher affinity for HPG estrogen receptors than estradiol itself → physically blocks estradiol from binding → brain perceives “catastrophic hypoestrogenism emergency” → GnRH cranks up → tsunami of LH + FSH → Leydig cells max to your genetic ceiling (cannot overdrive) + Sertoli cells dramatically increase spermatogenesis. You unleash what’s already there. Fertility is preserved.

For a young man with secondary hypogonadism (low T from a stalled HPG, not a broken factory) who wants kids in the future, the choice is not subtle. For an older man with primary hypogonadism who has already had his kids, TRT is the right tool. The question is the failure point, not which peptide is “better.”

---

Lever 1: Enclomiphene

What it is

A SERM (selective estrogen receptor modulator) — specifically the trans isomer of clomiphene citrate. Clomid (clomiphene citrate) is a 50/50 mix of two isomers: enclomiphene (the trans isomer, anti-estrogenic at the HPG estrogen receptors) and zuclomiphene (the cis isomer, estrogenic and long-acting, source of most of Clomid’s side effects). Pure enclomiphene = “clean Clomid” — the active half without the slow-clearing estrogenic baggage.

Zero testosterone in the molecule. Enclomiphene is not an androgen, not a steroid, not a hormone. It’s a competitive antagonist that blocks estradiol from binding to its HPG receptors.

How it works

• Higher affinity for hypothalamic + pituitary estrogen receptors than estradiol itself.
• Physically blocks estradiol from binding → brain interprets the blocked signal as “catastrophic hypoestrogenism emergency.”
• GnRH pulse amplitude and frequency crank up dramatically.
• Pituitary gonadotrophs hypersensitize → tsunami of LH + FSH.
• LH flood → Leydig cells max out T production to the individual’s genetic ceiling (you cannot overdrive what your factory is capable of).
• FSH surge → Sertoli cells dramatically increase spermatogenesis.

What the research shows

• The strongest indication is male fertility. Enclomiphene is the only tool that simultaneously elevates testosterone and enhances sperm production via FSH — neither TRT nor HCG does both. One practitioner’s framing of this is blunt: many male-infertility cases routed to $$$ IVF have not been tested on enclomiphene first.
• LH/FSH surge magnitudes in male hypogonadism trials.
• In women, the same SERM mechanism is FDA-approved as the original Clomid indication — ovulation induction for fertility (blocks midcycle estrogen feedback → triggers FSH + LH surge).

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

• Form: oral pill (the only non-injectable in this cluster).
• Community dose for male hypogonadism: 12.5–25 mg/day, often dosed daily; some users do EOD (every other day).
• Cycle: continuous use is common; some users cycle 12 weeks on / 4 weeks off to assess HPG function without enclomiphene support.
• Blood work to track: Total T, free T, LH, FSH, estradiol, SHBG. Baseline + 6–8 weeks + 12 weeks.

Side effects

• Generally clean compared to clomiphene citrate (the zuclomiphene component carries most of the Clomid side-effect load).
• Possible: mood changes, headaches, visual disturbances (rare, classically associated with high-dose clomiphene).
• Vision changes that don’t resolve = stop and re-evaluate.

Regulatory status

Not currently FDA-approved for male hypogonadism in the US — used off-label. Clomiphene citrate (Clomid) is approved for female infertility. Pure enclomiphene was pursued by Repros Therapeutics; a New Drug Application was filed but development hit regulatory headwinds.

---

Lever 2: HCG (human chorionic gonadotropin)

What it is

A glycoprotein hormone originally isolated from the placenta. HCG mimics LH at the testicular Leydig-cell receptor — it’s the LH analog that stimulates testosterone production directly at the testes, bypassing the hypothalamus and pituitary entirely. Long historical clinical use including pediatric undescended-testis treatment, fertility, and as a “rescue” for TRT users to keep testicular volume and intratesticular testosterone (which is critical for spermatogenesis) online.

How it works

• Binds the LH receptor on Leydig cells.
• Activates the cAMP / steroidogenesis pathway → testosterone production.
• Maintains testicular volume and intratesticular testosterone — which is why TRT users add HCG to preserve fertility and prevent the testicular atrophy that comes with full HPG suppression.

What the research shows

• Long clinical use; well-characterized at the level of mechanism and outcomes.
• TRT-adjuvant use case (preserves testicular volume and intratesticular T) is the most common modern indication.

The regulatory backstory — and why it matters for the supply-chain conversation

Per Neal’s clinical experience: HCG has been regulatory-targeted multiple times in the US, with pressure to block compounding pharmacies from producing it. His direct read, as a conservative clinician who prescribes it: “They make it exactly the same way. There’s absolutely no difference between the brand name and the compounding pharmacy. Zero health risks involved with it at all. It’s strictly a money thing.”

That’s a clinician openly defending the quality of verified compounding pharmacies — which lines up directly with the broader supply-chain story Alyve sits inside. The framing that helps OHM readers parse this honestly: verified compounders (with third-party COAs, like Alyve’s Freedom Diagnostics testing model) make products that are clinically equivalent to brand-name. Unverified gray-market compounders are a different category and a real risk. The “compounded is scary” general framing collapses both categories into one and is partly Big Pharma marketing pressure rather than a quality reality.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

• TRT-adjuvant dose (community-typical): 250–500 IU SubQ, 2–3×/week.
• Reconstitution: HCG vials are dosed in international units (IU), not mg — reconstitution depends on vial strength (commonly 5,000 or 10,000 IU per vial) and amount of bacteriostatic water used. Verify with the specific product.
• Route: subcutaneous injection.
• Cycle: continuous co-administration with TRT is the most common pattern; standalone HCG monotherapy is used less often.

Side effects

• Generally well-tolerated at TRT-adjuvant doses.
• Higher-dose HCG can drive significant estradiol via Leydig-cell-localized aromatase — monitoring estradiol is part of the protocol.
• Gynecomastia risk if estradiol rises uncontrolled.

Regulatory status

FDA-approved historically for several indications; the brand-name vs. compounding-pharmacy access landscape has cycled multiple times. Banned by WADA for sport (S2 — peptide hormones, growth factors). Per Neal: access “will come back around” — historical precedent suggests compounded access cycles.

---

Lever 3: Gonadorelin

What it is

Synthetic GnRH — the same 10-amino-acid decapeptide your hypothalamus secretes. Gonadorelin is the GnRH molecule itself, provided exogenously. It acts one step up from HCG (which is at the testicles) and one step down from kisspeptin (which is upstream of GnRH).

How it works

• Binds GnRH receptors on pituitary gonadotrophs.
• Triggers LH + FSH release.
• Critical: must be dosed pulsatile, not constant. Constant GnRH exposure desensitizes the pituitary (this is actually how GnRH agonists work as chemical castration in prostate cancer — opposite effect). For HPG restoration, gonadorelin must mimic the natural pulsatile rhythm — typically multiple small injections per day or via a pump.

What the research shows

• Long-established pharmacology — gonadorelin = GnRH; the mechanism is textbook endocrinology.
• Clinical use historically in pulsatile-pump format for hypogonadotropic hypogonadism (Kallmann syndrome, idiopathic hypogonadotropic hypogonadism).
• More recent off-label use as a TRT-adjuvant (replacement for HCG when HCG access has been limited).

Real-world protocol

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

• Pulsatile dosing is non-negotiable. Constant exposure desensitizes the receptor and produces the opposite effect.
• Community-typical TRT-adjuvant dose: 100–300 mcg SubQ, multiple times per day (often 2–3× daily).
• Half-life is short (minutes range) — this is why it must be pulsatile; a single daily bolus produces a brief spike and nothing else.
• Reconstitution: typical 5 mg vial + 5 mL bacteriostatic water = 1 mg/mL = 100 mcg per 10 units on a U-100 insulin syringe.

Side effects

• Generally well-tolerated.
• Constant (non-pulsatile) dosing produces paradoxical pituitary desensitization — the most common protocol error.

Regulatory status

Used historically as a diagnostic agent (GnRH stimulation test). Available via compounding pharmacies. Banned by WADA for sport (same class as HCG).

---

Lever 4: Kisspeptin — the upstream-most lever

See the dedicated Kisspeptin wiki article for the full treatment (mechanism, evidence, one practitioner “master regulator” framing, dosing protocol). Brief summary here for the cluster:

• What it is: the natural endogenous ligand for the kisspeptin receptor (KISS1R). The kisspeptin neuron in the hypothalamus is one step upstream of the GnRH neuron — kisspeptin is what initiates GnRH pulsatility.
• Where it acts: the very top of the HPG cascade.
• One practitioner’s framing: when paired with enclomiphene, “the pinnacle of biohacking synergy” — enclomiphene removes the estrogen-feedback brake, kisspeptin stomps on the GnRH-pulsatility gas pedal. Two complementary upstream levers.
• Short half-life: must be dosed frequently — typically more than twice weekly, sometimes daily.
• Status: parallel wiki article (Kisspeptin) covers this in depth.

---

Aromatase inhibitors — the separate tool class

Worth naming briefly because the one practitioner + Neal sources both raise it: aromatase inhibitors (AIs) — anastrozole, exemestane, letrozole — are the separate tool class that reduces T → estradiol conversion. They sit parallel to the four levers above, not in the cascade.

The critical balance principle (Neal): “Having too much estrogen is a problem. Having too little estrogen is also a problem.” Men need some estrogen for bone density, mood, libido, lipids. Crashing estrogen via aggressive AI use is its own clinical syndrome (joint pain, libido loss, low mood, bone-density problems). AI users need to monitor estradiol, not just total T.

This article doesn’t cover AIs in depth — they’re a separate cluster — but flag them here because they often come up in the same TRT-protocol-management conversation.

---

Where experts disagree

• TRT vs. Enclomiphene as first-line for secondary hypogonadism. One practitioner’s reading is that enclomiphene is the smarter first-line tool for secondary hypogonadism because it preserves fertility and native production. The conventional-endocrinology reading is that TRT is the standard of care and enclomiphene is off-label. Both agree on the diagnosis (the blood-work pattern); the disagreement is about which tool to reach for in the secondary-hypogonadism case.
• Combination protocols (TRT + Enclomiphene simultaneously). One practitioner’s read: often fails because the combined negative-feedback steroid load is too powerful, and the result is Leydig + Sertoli burnout. Neal’s read: combination is possible because the compounds act at different points of the cascade, but it’s high-risk endocrinology that requires extensive blood work. Both agree it’s not for self-experimentation without monitoring.
• Compounded HCG and gonadorelin quality. Neal directly contradicts the “compounded is scary” framing for verified compounding pharmacies. Other clinicians (e.g., Tyna Moore’s compounding-pharmacist friend in a separate KB digest) raise legitimate concerns about unverified gray-market compounding. The honest reconciliation: verified compounders with third-party COAs (Alyve’s model) are clinically equivalent to brand-name; unverified compounders are a real risk. The framing matters.
• Gonadorelin pulsatility in practice. The textbook answer is pulsatile dosing via pump or multiple-times-daily injection. The biohacker community sometimes runs once- or twice-daily dosing for convenience and reports clinical effect — but the formal pharmacology says constant/infrequent exposure desensitizes. The biohacker pattern is extrapolation; the trial-validated pattern is pulsatile.

The "testosterone rage" myth — worth flagging because it gates many users

A user reading about TRT vs. Enclomiphene will run into the “TRT will make you angry” narrative within ten seconds of searching. One practitioner’s three-prong reframe (worth holding in mind because it changes how the whole cluster’s protocols read):

1. GABAergic upregulation. Testosterone and its metabolites enhance GABA-A receptor function — GABA is the brain’s primary inhibitory neurotransmitter / brake pedal. Properly dosed T = more effective brain brake, not less.
2. Amygdala calibration. Low T → hyperreactive amygdala (oversensitive threat detection: irritability, anxiety, perceiving threats that aren’t there). Healthy T → calibrated amygdala — “smarter alarm,” fires on legitimate threats only.
3. BDNF. Testosterone increases BDNF (brain-derived neurotrophic factor). Low T is associated with low BDNF, which produces cognitive decline, brain fog, depression, and poor emotional regulation. Restoring T → BDNF rises → cognitive and emotional function improve.

The actual cause of “rage” on TRT is usually estrogen imbalance from poor protocol management — too much T → aromatization → high estradiol → water retention (including brain), bloating, mood swings, tearfulness, irrational irritability. It’s an aromatase / estradiol management problem, not a testosterone problem.

One practitioner’s bonus reframe — useful for OHM voice across all these protocols: “Hormones don’t create personality traits. They amplify the existing ones.” TRT will not fix your character. It will give you more energy to be whatever you already are.

---

A note on women and these compounds

All four levers + TRT can be used in women, but the therapeutic window is much narrower and the consequences are different:

• Enclomiphene’s FDA-approved use in women is ovulation induction for fertility (the original Clomid indication) — blocking midcycle estrogen feedback triggers an FSH/LH surge.
• Using any of these compounds to raise testosterone in women carries a real and irreversible virilization risk — voice changes, body-hair pattern, clitoral enlargement do not reverse if you stop. This is not a small caveat; it’s the central operational risk for female users of any of these tools.
• Female-specific protocols and outcomes are out of scope for this article and belong in a dedicated piece. Any OHM content directed at female audiences must surface the irreversibility risk prominently.

---

The Alyve product (commercial layer)

None of Enclomiphene, HCG, Gonadorelin, or Kisspeptin is in Alyve’s current launch 15-SKU catalog — all four are flagged as roadmap candidates.

• HCG — strong catalog-expansion candidate. Clinical demand is substantial (every TRT user is a candidate), the regulatory access pattern cycles (Neal’s “it’ll come back around”), and the supply-chain quality framing maps directly onto Alyve’s verified-vendor positioning.
• Enclomiphene — strong candidate. Men’s-health demand is high, the fertility-preserving angle is a distinct lane vs. TRT clinics, and it would be the only pill in the catalog.
• Gonadorelin — niche but valuable. The pulsatile-dosing-protocol education is a content moat.
• Kisspeptin — niche but pairs with enclomiphene for the “pinnacle synergy” content angle (see Kisspeptin).

What Alyve carries today for this audience. The cross-sell that is live for TRT-users right now is the GH-axis rescue:

• Ipamorelin — one practitioner’s explicit adjuvant recommendation for testosterone users. Exogenous testosterone suppresses native GH pulsatility; ipamorelin (selective GHS-R1a agonist) restores it. Synergistic anabolic + recovery effect. This is the first explicit one practitioner Alyve-SKU recommendation in the source material.
• CJC-1295 / Ipamorelin — the dual-receptor GH stack (GHRH analog + ghrelin-receptor agonist) for fuller GH pulse restoration on top of TRT.

The supply-chain trust story. Independent gray-market peptide testing has consistently found roughly 1 in 4 vials underdosed, mislabeled, or contaminated. Alyve answers that with US manufacturing + third-party Freedom Diagnostics COAs + verified >99% purity across the catalog. Neal’s HCG defense is the same logic from a clinician’s angle: verified compounding is clinically equivalent to brand-name; the framing that conflates verified and unverified compounding is mostly marketing.

Use code OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. For this audience today, the practical bulk-stack play is 3 vials of CJC-1295 / Ipamorelin (the TRT-adjuvant GH rescue) or 3 vials of Ipamorelin alone.

Sources

• the TRT vs. Enclomiphene framing, HPG axis mechanism map, decision algorithm, rage-myth demolition, adjuvant stack (Ipamorelin for T users, Kisspeptin for enclomiphene users).
• the 4-tool cascade-failure-point map, HCG regulatory + compounding-pharmacy defense, aromatase-inhibitor balance principle, estrogen-not-testosterone-flips-switch framing.
• kisspeptin upstream-of-GnRH framing (covered in depth in Kisspeptin).
• verified-supply baseline for the cluster-adjacent SKUs (Ipamorelin, CJC-1295 / Ipamorelin) that are in catalog.
• Established endocrinology: HPG axis cascade, aromatase, SERM mechanism, primary vs. secondary hypogonadism distinction.

Related: Kisspeptin · Ipamorelin · CJC-1295 / Ipamorelin · CJC-1295 · Sermorelin · Tesamorelin.